Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reply to Correspondence

Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):e226-e227. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0128

View: 885 Download: 26

Correspondence

Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):e186-e188. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0079

View: 628 Download: 36 Crossref: 1

Editorial

Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Nahee Hwang, Sungsoon Fang

Clin Mol Hepatol. 2025;31(2):631-634. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0066

View: 887 Download: 44 Crossref: 2

Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):628-630. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0036

View: 1024 Download: 41 Crossref: 2

Original Article

GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Xiao-Chen Ma, Chen-He Yi, Bao-Rui Tao, Bo Zhang, Yue Ma, Guo Zhang, Rui Zhang, Yan Geng, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):409-425. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0657

View: 2004 Download: 264 Crossref: 7

Letter to the Editor

Functional cure of chronic hepatitis B encounters resmetirom

Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng

Clin Mol Hepatol. 2024;30(3):580-581. Published online April 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0301

View: 2762 Download: 114 Web of Science: 2 Crossref: 2

Original Article

Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy

Qi Wang, Qingfa Bu, Zibo Xu, Yuan Liang, Jinren Zhou, Yufeng Pan, Haoming Zhou, Ling Lu

Clin Mol Hepatol. 2024;30(3):515-538. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0107

View: 5030 Download: 315 Web of Science: 5 Crossref: 5

1 |

Viewed By 10751	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7579	MAFLD: How is it different from NAFLD?
Viewed By 5466	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4918	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 4853	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 338	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search